+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hospital Acquired Infection"

From
From
From
From
From
Pseudomonas aeruginosa infection - Pipeline Insight, 2024 - Product Thumbnail Image

Pseudomonas aeruginosa infection - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Clostridium Difficile Infections - Pipeline Insight, 2024 - Product Thumbnail Image

Clostridium Difficile Infections - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
From
Nosocomial Pneumonia - Pipeline Insight, 2024 - Product Thumbnail Image

Nosocomial Pneumonia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Klebsiella Infections - Pipeline Insight, 2024 - Product Thumbnail Image

Klebsiella Infections - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
From
From
From
From
Loading Indicator

The Hospital Acquired Infection (HAI) market is a subset of the Infectious Diseases Drugs market. HAIs are infections that occur in a hospital setting, and can be caused by a variety of bacteria, viruses, and fungi. These infections can be difficult to treat, as they are often resistant to antibiotics. As such, HAI drugs are designed to target specific pathogens, and are often used in combination with other treatments. The HAI market is driven by the increasing prevalence of antibiotic-resistant infections, as well as the need for more effective treatments. Additionally, the rising number of hospitalizations due to chronic illnesses has also contributed to the growth of the market. Some of the major players in the HAI market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, and Johnson & Johnson. These companies are actively developing new drugs and treatments to address the growing prevalence of HAIs. Show Less Read more